Randomized Comparison of Goserelin Acetate versus Mitomycin C plus Goserelin Acetate in Previously Untreated Prostate Cancer Patients with Bone Metastases
暂无分享,去创建一个
L. Dogliotti | O. Bertetto | D. Fontana | A. Berruti | G. Pagani | S. Pallotti | G. Fasolis | R. Tarabuzzi | T. Buniva | R. Zolfanelli | L. Frezzotti | C. Bumma | S. R. Rossetti | G. Pagani | Dario Fontana | S. Rossetti | Silvio Pallotti | Letizia Frezzotti
[1] R. Paridaens,et al. Interim Results on a Randomized Trial of Mitomycin C in Combination with Orchidectomy for Newly Diagnosed Metastatic Prostate Cancer , 1995, American journal of clinical oncology.
[2] H. Yamanaka,et al. Chemo‐endocrine therapy in patients with stage D2 prostate cancer , 1995, The Prostate.
[3] S. Fosså,et al. Assessment of quality of life in patients with prostate cancer. , 1994, Seminars in oncology.
[4] K. Griffiths,et al. Hormonal treatment of advanced disease: some newer aspects. , 1994, Seminars in oncology.
[5] B. Redman,et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Vessella,et al. Newer applications of serum prostate-specific antigen in the management of prostate cancer. , 1994, Seminars in oncology.
[7] S. Rosso,et al. Cancer Incidence in Turin: The Effect of Migration , 1993, Tumori.
[8] J. Miller,et al. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. , 1992, The Journal of urology.
[9] G. Murphy,et al. A comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylstilbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate , 1988, Cancer.
[10] T. Guthrie,et al. Prostate cancer. , 2020, American family physician.
[11] R. Gibbons. Prostate cancer. Chemotherapy , 1987, Cancer.
[12] R. Priore,et al. Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. , 1986, Urology.
[13] J. Isaacs. The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer , 1984, The Prostate.
[14] P. Scardino,et al. Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone , 1983, Cancer.
[15] D. S. Coffey,et al. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. , 1981, Cancer research.
[16] R. Melzack. The McGill Pain Questionnaire: Major properties and scoring methods , 1975, PAIN.